Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma

Status Completed

Clinical Trial Summary

Our aim was to systematically evaluate the current data on the efficacy of pretreatment with either selective or nonselective alpha-blockade on the hemodynamic instability and morbidity during pheochromocytoma resection.

Clinical Trial Description

RCTs and non-randomized controlled studies comparing preoperative selective alpha-blockade (SAB) with nonselective alpha-blockade (NAB) in pheochromocytoma surgery in adults were eligible for inclusion. All identified articles will be screened by title and abstract. Two independent reviewers will review potentially relevant articles in detail. Dissent will be resolved by consensus and the recommendation of a third observer as required. Data from the included studies will be extracted independently by the two researchers. The Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines will be used for reporting. Quality of Assessment The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool will be used to assess the quality of included non-randomized studies. The risk of bias of randomized studies will be assessed using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions .The quality of each study will be assessed by two of the authors. In the event of uncertainties regarding the levels of the studies' quality, a third reviewer will be consulted. Analysis will be performed using RevMan (Version 5.3, freeware from the Cochrane Collaboration). Odds ratios and their associated 95% confidence intervals will be pooled for dichotomous outcomes using the Mantel-Haenszel random-effects method. Continuous outcomes will be pooled as weighted mean difference (WMD) with 95 per cent confidence interval using the inverse-variance random-effects method. WMD and OR will be presented on the graphs as squares, and pooled WMD and OR will be presented as diamond. P ≤ 0.05 will be considered a statistically significant difference for hypothesis and P < 0.10 for heterogeneity testing, respectively. Heterogeneity between the studies will be estimated by statistical tests I2 and Cochran's Q tests. ;

Study Design

Related Conditions & MeSH terms

Pheochromocytoma

Clinical Trial Details

NCT number	NCT04557072
Study type	Observational
Source	Jagiellonian University
Contact
Status	Completed
Phase
Start date	August 1, 2020
Completion date	November 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Terminated	`NCT05948137` - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Recruiting	`NCT05069220` - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor	Early Phase 1
Recruiting	`NCT06062082` - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting	`NCT04573816` - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Not yet recruiting	`NCT06045260` - "Receptor Radionuclide Therapy With 177Lu-DOTATOC	Phase 2
Completed	`NCT00001147` - Blood Sampling for Neurochemical and Genetic Testing	N/A
Terminated	`NCT00002947` - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer	Phase 1
Completed	`NCT00001229` - Diagnosis and Treatment of Pheochromocytoma	N/A
Completed	`NCT01967576` - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma	Phase 2
Recruiting	`NCT03160274` - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting	`NCT03206060` - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	Phase 2
Not yet recruiting	`NCT04788927` - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms